Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ascendis Pharma (ASND)
NASDAQ:ASND
Holding ASND?
Track your performance easily
ASND Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$85.29 - $161.00
Previous Close$142.67
Volume340.46K
Average Volume (3M)597.81K
Market Cap
$8.08B
Enterprise Value$8.36B
Total Cash (Recent Filing)€399.44M
Total Debt (Recent Filing)€644.26M
Price to Earnings (P/E)―
Beta0.81
Next Earnings
Nov 06, 2024EPS Estimate
-$1.69Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-9.34
Shares Outstanding56,614,385
10 Day Avg. Volume467,619
30 Day Avg. Volume597,808
Standard Deviation0.12
R-Squared0.08
Alpha0.00603
Financial Highlights & Ratios
Price to Book (P/B)-55.51
Price to Sales (P/S)26.85
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$196.54Price Target Upside37.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
Ascendis Pharma News
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyPhase 3 data demonstrates a profile which suggests safety and efficacy that is comparable to BioMarin's Voxzogo with 1/7 the number of injections.
Market PositionTransCon CNP’s weekly injection regimen is seen as a clear advantage over Voxzogo’s daily injection, likely driving higher uptake.
Market PotentialIf approved, TransCon CNP is expected to become the clear market leader in injectable treatments for achondroplasia.
Bears Say
EarningsThe spotlight was on disappointing Skytrofa news on the 2Q24 earnings conference call, overshadowing the interest on Yorvipath's launch.
Market AccessThe delay in getting the earnings conference call started did not help with the disappointing news that Skytrofa, along with the entire growth hormone market, was subject to a broader market access reset lowering the price of growth hormone agents.
Sales GuidanceDespite the increase in sales volume, the lower price of Skytrofa caused ASND to lower their FY24 Skytrofa sales guidance to €220-240M (from €320-340M).
---
Ownership Overview
6.50%
Insiders
28.29% Mutual Funds
<0.01% Other Institutional Investors
64.12% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ASND FAQ
What was Ascendis Pharma’s price range in the past 12 months?
Ascendis Pharma lowest stock price was $85.28 and its highest was $161.00 in the past 12 months.
What is Ascendis Pharma’s market cap?
Currently, no data Available
When is Ascendis Pharma’s upcoming earnings report date?
Ascendis Pharma’s upcoming earnings report date is Nov 06, 2024 which is in 32 days.
How were Ascendis Pharma’s earnings last quarter?
Ascendis Pharma released its earnings results on Sep 03, 2024. The company reported -$2.115 earnings per share for the quarter, missing the consensus estimate of -$1.614 by -$0.5.
Is Ascendis Pharma overvalued?
According to Wall Street analysts Ascendis Pharma’s price is currently Undervalued.
Does Ascendis Pharma pay dividends?
Ascendis Pharma does not currently pay dividends.
What is Ascendis Pharma’s EPS estimate?
Ascendis Pharma’s EPS estimate is -$1.69.
How many shares outstanding does Ascendis Pharma have?
Ascendis Pharma has 60,231,483 shares outstanding.
What happened to Ascendis Pharma’s price movement after its last earnings report?
Ascendis Pharma reported an EPS of -$2.115 in its last earnings report, missing expectations of -$1.614. Following the earnings report the stock price went down -11.271%.
Which hedge fund is a major shareholder of Ascendis Pharma?
Among the largest hedge funds holding Ascendis Pharma’s share is RA Capital Management. It holds Ascendis Pharma’s shares valued at 1B.
---
Ascendis Pharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$196.54 (37.76% Upside)
$196.54 (37.76% Upside)
Blogger Sentiment
Bullish
ASND Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 28.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 3.6%
Last 30 Days ▲ 5.6%
Last 30 Days ▲ 5.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
65.70%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-9.58%
Trailing 12-Months
Company Description
Ascendis Pharma
Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. Through its TransCon technology, it develops a pipeline of sustained release prodrug therapies including endocrinology product candidates to support the market. The company was founded by Jan Moller Mikkelsen and Harald Rau in September 2006 and is headquartered in Hellerup, Denmark.
---
ASND Earnings Call
Q2 2024
0:00 / 0:00
---
ASND Stock 12 Month Forecast
Average Price Target
$196.54
▲(37.76% Upside)
Technical Analysis
Best Analysts Covering ASND
1 Year
1 Year Success Rate
22/25 ratings generated profit
1 Year Average Return
+29.40%
assigned a buy rating 13 days ago
Copying Tazeen Ahmad's trades and holding each position for 1 Year would result in 88.00% of your transactions generating a profit, with an average return of +29.40% per trade.
---